Boston - Model BOS-475 - Bromodomain and Extra Terminal (BET) Inhibitor

BOS-475 is a selective BET (bromodomain and extra terminal) inhibitor. BOS-475 potently inhibits multiple clinically validated pathways (IL-12/IL-23-p40, Th17 cytokines and TNF) relevant to psoriasis pathophysiology. BOS-475 demonstrates broad inhibitory activities on other key disease-relevant immune-inflammatory mediators such as MCP-1, IL-6, and CXCL10 & 11. Topical BOS-475 is a potential treatment for psoriasis and other inflammatory skin diseases.